Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.

Our analysis showed that, compared with other previously described intra-tumoral immune cell markers associated response such as CD8 and IFNG, differences in IGHG1 expression between treatment PR, SD, and PD were highly significant.

also in 132,142 other papers

We also observed a strong trend toward increased PFS in the IGHG1_exp = high group, though statistical significance was not reached ( Fig. 3C ).

also in 5,725 other papers